Labcorp Partners with Roche to Deploy Digital Pathology Technology Amid Growing Pathologist Shortage
核心洞察
Labcorp has partnered with Roche to implement FDA-cleared VENTANA DP 600 (搜索) and DP 200 slide scanners, enabling pathologists to diagnose patients using digital images instead of traditional microscopes.
The collaboration addresses a critical healthcare challenge, as the U.S. faces a projected shortage of nearly 5,700 pathologists by 2030 while demand for diagnostic services continues to grow.
Digital pathology technology converts glass slides into high-resolution digital images that can be viewed remotely, streamlining workflows and establishing a foundation for future AI integration.
Labcorp, a global leader in laboratory services, has announced a strategic collaboration with Roche to implement digital pathology technology across its anatomic pathology services. The partnership involves deploying Roche's FDA-cleared VENTANA DP 600 (搜索) and DP 200 slide scanners, marking a significant step toward modernizing diagnostic workflows and addressing critical healthcare challenges.
Addressing Critical Healthcare Workforce Shortage
The collaboration comes at a pivotal time for the pathology field. The United States faces a projected shortage of nearly 5,700 pathologists by 2030, while demand for diagnostic services continues to escalate due to an aging population and increasing incidence of cancer (搜索) and other diseases. This workforce gap threatens to impact patient care and diagnostic turnaround times across healthcare systems.
"Labcorp is committed to advancing its diagnostic capabilities through the adoption of innovative technologies," said Marcia Eisenberg, Ph.D., Labcorp's chief scientific officer. "Integrating digital slide scanning into our pathology workflow will help improve accuracy, streamline operations and enable future AI-driven insights."
Digital Transformation of Pathology Workflows
The digital pathology system converts traditional glass slides into high-resolution digital images that can be instantly viewed using conventional PC workstations rather than microscopes. This transformation enables pathologists to analyze and share diagnostic information from any location, eliminating dependence on physical slides and allowing specialists to operate across multiple sites.
Key operational benefits of the digital pathology implementation include improved access to specialized expertise through remote sharing capabilities, enhanced workflow efficiency by eliminating physical slide handling and transportation requirements, and reduced operational costs and risks associated with slide damage or loss of irreplaceable tissue samples.
Foundation for AI Integration
The digital infrastructure establishes a critical foundation for artificial intelligence tools that can enhance consistency, accuracy, and efficiency in pathology workflows. This technological advancement positions Labcorp to leverage future AI-driven diagnostic insights while maintaining current diagnostic standards.
Michael Rivers, life cycle leader for digital pathology at Roche Tissue Diagnostics (搜索), emphasized the collaboration's potential impact: "This collaboration, which combines Labcorp's strength in diagnostic services with Roche's expertise in digital pathology solutions, holds the potential to create new opportunities for highly efficient, timely and effective patient care."
Expanding Global Clinical Trial Capabilities
The partnership extends Labcorp's existing relationship with Roche and builds upon the company's digital pathology portfolio for oncology services. Labcorp teams currently utilize digital pathology technology globally to support clinical trials, enabling more efficient data sharing, centralized review processes, and accelerated decision-making timelines.
The investment represents part of Labcorp's broader commitment to expanding digital capabilities across its Diagnostics and Biopharma Laboratory Services business segments. With nearly 70,000 employees serving clients in approximately 100 countries, Labcorp provided support for more than 75% of new drugs and therapeutic products approved by the FDA in 2024 and performs over 700 million tests annually worldwide.